Llistat de guanyadors de la beca internacional Josep Carreras - E.D Thomas

  • 1991-1992-1993: Dr. Catherine Verfaillie, University of Minnesota (Estats Units). CML: purification of bening stem cells useful for autologous transplant and generation of autologous A-LAK suitable for post-transplant consolidation.
  • 1992-1993-1994: Dr. Alessandra Cesano, The Winstar Institute (Estats Units). An in-vivo model of cell-mediated lyisi against acute lymphoblastic leukemia.
  • 1993-1994-1995: Dr. Ana Carrera, Fundación Severo Ochoa / Centro de Biología Molecular / Universidad Autónoma de Madrid (Espanya). Study of the effects of pp56lck mutants with substrate specificity on cell transformation.
  • 1993-1994-1995: Dr. Robert S. Negrin, Standford University Hospital (Estats Units). Biology of cytokine induced natural killer cells.
  • 1994-1995-1996: Dr. Bruce C. Clurman, Fred Hutchinson Cancer Research Center (Estats Units). Targeted disruption of Aessential genes in lymphoma cells.
  • 1995-1996-1997: Dr. I. Sanchez-García, Instituto de Microbiología Bioquímica CSIC / Universidad de Salamanca (Espanya). Gene therapy for the treatment of Philadelphia cromosome-positive leukaemia.
  • 1996-1997-1998: Dr. Martin Stattler, Dana-Farber Cancer Institute, Boston (Estats Units). Role of Activationof Stat Proteins by BCR/ABL in the pathogenesis of chronic myeloid leukemia (CML).
  • 1997-1998-1999: Dr. Ralf Huss, Institute of Pathology, University of Munich (Alemanya). Mechanisms of differentiation, proliferation and cell clycle progression in hematopoietic stem cells: a model for leukemic transformation.
  • 1997-1998-1999: Dr. Mathew Fero, Fred Hutchinson Cancer Research Center, Seattle (Estats Units). Tumor suppression by CDK Inhibitors.
  • 1998-1999-2000: Dr. Koichi Akashi, Stanford University School of Medicine (Estats Units). Identification of Human Common Lymphoid Progenitor.
  • 1999-2000-2001: Dr. Francesco Galimi, The Salk Institute, La Jolla, California (Estats Units). Role of Telomere Maintenance in Human Hematopoietic Stem Cells: A Gene Transfer Approach.
  • 2000-2001-2002: Dr. Claudia Huettner, Beth Israel Deaconess Medical Center - Harvard Institutes of Medicine (Estats Units). Conditional transgenic models of BCR/ABL leukemia.
  • 2000-2001-2002: Dr. Soheil Meshinchi, Fred Hutchinson Cancer Research Center, Seattle (Estats Units). Biologic and clinical significance of Flt3 internal tandem duplication in pediatric Acute Myeloid Leukemia.
  • 2000-2001-2002: Dr. Elena Tassi, Instituto Nazionale Tumori Milano (Itàlia). Molecular Mechanism involved in the resistance to BCR/ABL inhibition in neoplastic cells (va renuciar a la beca que va ser concedida posteriorment a la Dra. Gumby).
  • 2000-2001-2002: Dra. Rosalind Gunby, Instituto Nazionale Tumori Milano (Itàlia). Investigation of the Mechanisms of resistance to the BCR/ABL inhibitor STI571.
  • 2001-2002-2003: Dr. Homayoun Vaziri, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts (Estats Units). Molecular determinants of cellular senescense and immortalization.
  • 2002-2003-2004: Dr. Emmanuelle Pessegue, Stanford University (Estats Units). Towards a better understanding of molecular mechanisms of myeloid leukemia.
  • 2003-2004-2005: Dr. Alejandro Barbieri, Washington University School of Medicine (Estats Units). Role of Ras interference 1 (rin) in acute and chronic myelogenous leukaemias.
  • 2004-2005-2006: Dr. Yukiko Yamashita, Stanford University (Estats Units). The mechanisms that control stem cell fate between proliferation and differentiation by asymmetric stem cell division.
  • 2005-2006-2007: Dr. Golam Mohi, Beth Israel Deaconess Medical Center - Harvard Medical School, Boston (Estats Units). The Gab2/Shp2 Pathway in Human leukaemia.
  • 2006-2007-2008: Dr. Pablo Menéndez, Institute of Cancer Research- Chester Beatty Laboratories, London (Anglaterra). Developmental Impact of MLL-AF4 Leukaemic Fusion Gene on Human Stem Cell Fate.
  • 2007-2008-2009: Dr. Karl Novina, Dana Farber Cancer Institute, Boston (Estats Units). Mouse modeling of Micro-RNA function in chronic lymphocytic leukemia.
  • 2008-2009-2010: Dr. Jean François Rual, Harvard Medical School - Dept. of Cell Biology, Boston (Estats Units). Molecular and Genetic definition of the Notch signalling network, a major factor in T-ALL.
  • 2009-2010-2011: Dr. Hanna Cullup, Mater Medical Research Institute South Brisbane (Austràlia). Antibody-mediated dendritic cell depletion to attenuate GVHD and promote GVL.
  • 2010-2011-2012: Dr. Adlen Foudi, Harvard Medical School, Stem Cell Institute, Boston (Estats Units). Role of Gfi-1 family of transcriptional repressors in normal hematopoiesis and leukaemia.
  • 2011-2012-2013: Dr. Robert S. Welner, Ph.D. Beth Israel Deaconess, Boston (Estats Units). β-catenin maintains leukemic stem cells by suppressing transcription factors required for differentiation.
  • 2012-2013-2014: Dr. Pedro Pablo Medina, Kline Biology Laboratory, Yale University (Estats Units). Micro-RNA-21 induced haematological malignancies.
  • 2013-2014-2015: Dr. Thomas Schmitt, Fred Hutchinson Cancer Research Center, Seattle (Estats Units). Targeting Leukemia with Enhanced-Affinity TCR Gene Therapy.
Pàgina web actualitzada 19/01/2022 10:40:14

Fes un donatiu